Organogenesis

Organogenesis(ORGO)

CANTON, MA
Biotechnology
WebsiteLinkedInCareers Page

Focus: Biologics

Organogenesis is a life sciences company focused on Biologics.

Regenerative MedicineBiologicsWound CareUnknown
Funding Stage
PUBLIC
Open Jobs
4

Pipeline & Clinical Trials

NuTech Affinity™ Membrane
Chondral Lesions
N/A
Clinical Trials (1)
NCT02837484NuTech Affinity™ for the Treatment of Chondral Defects
N/A
Affinity human amniotic membrane
Diabetic Foot Ulcer
N/A
Clinical Trials (1)
NCT03205436Affinity Prospective Diabetic Foot Trial Crossover Group
N/A
N/A
Clinical Trials (1)
NCT01134081Expression of Angiogenic Biomarkers During Healing of Intra-Oral Soft Tissue Engineered Grafts
N/A
Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Pressure Wound Therapy System
Diabetic Foot Ulcer
N/A
Clinical Trials (1)
NCT01623882Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Pressure Wound Therapy System
N/A
One or two level lumbar interbody fusion surgery
Degenerative Disc Disease
N/A
Clinical Trials (1)
NCT02808234Study of Nucel for One and Two Level Lumbar Interbody Fusion
N/A
Affinity Allograft
Diabetic Foot Ulcers
N/A
Clinical Trials (1)
NCT02880592Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers
N/A
PuraPly™ Antimicrobial Wound Matrix
Partial Thickness Wound
N/A
Clinical Trials (1)
NCT03286452The RESPOND Registry
N/A
NuCel with Autograft
Intervertebral Disc Disease
N/A
Clinical Trials (1)
NCT02023372Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine
N/A
N/A
Clinical Trials (1)
NCT04901013Clinical Study Of Affinity Versus SOC In The Management Of VLUs
N/A
VCT-01
Wounds
N/A
Clinical Trials (1)
NCT01292122Safety Study of VCT-01™ in Split-Thickness Skin Graft Donor Site Wounds
N/A
N/A
Clinical Trials (1)
NCT01547962A Pilot Clinical Trial of Gintuit (TM)in Establishing a Functional Zone of Attached Gingiva
N/A
PuraPly™ Antimicrobial Wound Matrix
Pressure Ulcer
N/A
Clinical Trials (1)
NCT03070938PuraPly™ Antimicrobial Wound Matrix and Wound Management
N/A
N/A
Clinical Trials (1)
NCT03855514Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers
N/A
Standard of Care
Diabetic Foot Ulcer
N/A
Clinical Trials (1)
NCT06618612A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers
N/A
ReNu™ Injection
Osteoarthritis, Hip
N/A
Clinical Trials (1)
NCT03063099ReNu™ Injection to Treat Hip Osteoarthritis Study
N/A
PuraPly™ Antimicrobial Wound Matrix
Pressure Ulcers
N/A
Clinical Trials (1)
NCT03070925Prospective PuraPly™ AM Case Series Study
N/A
PuraPly® Antimicrobial Wound Matrix
Chronic Pressure Ulcers
N/A
Clinical Trials (1)
NCT03502824PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.
N/A
Knee injection
Osteoarthritis
N/A
Clinical Trials (1)
NCT02318511An Investigation of ReNu™ Knee Injection in Patients With Osteoarthritis
N/A
N/A
Clinical Trials (1)
NCT03036878ReNu™ Marrow Stimulation Augmentation
N/A
ReNu Injection
Fasciitis, Plantar
N/A
Clinical Trials (1)
NCT02982226ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis
N/A
N/A
Clinical Trials (1)
NCT02461641NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers
N/A
N/A
Clinical Trials (1)
NCT03828916NuShield in Surgical Peroneal Tendon Repair
N/A
Phase 1/2
Clinical Trials (1)
NCT01929954Safety Study of Gintuit™ in Subjects Requiring Socket Grafting
Phase 1/2
Phase 1/2
Clinical Trials (1)
NCT00679081A Pilot Study of CelTx(TM) (Apligraf®) in the Treatment of Gingival Recession Requiring Root Coverage
Phase 1/2
Apligraf
Keloid
Phase 1/2
Clinical Trials (1)
NCT00587587A Pilot Study of Apligraf for the Treatment and Prevention of Recurrence of Excised Keloids
Phase 1/2
Phase 3
Clinical Trials (1)
NCT00587223Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)
Phase 3
Phase 3
Clinical Trials (1)
NCT01181453Pivotal Trial of Dermagraft(R) to Treat Diabetic Foot Ulcers
Phase 3
Phase 3
Clinical Trials (1)
NCT01181440Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers
Phase 3
Phase 3
Clinical Trials (1)
NCT00587834Safety and Efficacy of Gintuit(TM)for Oral Soft Tissue Regeneration
Phase 3
Amniotic Suspension Allograft
Knee Osteoarthritis
Phase 3
Clinical Trials (1)
NCT06000410A Study to Evaluate the Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
Phase 3
Bi-layered cell therapy
Diabetic Foot
Phase 3
Clinical Trials (1)
NCT00512538Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers
Phase 3
Phase 3
Clinical Trials (1)
NCT00909870Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Phase 3
Amniotic Suspension Allograft
Knee Osteoarthritis
Phase 3
Clinical Trials (1)
NCT04636229Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee
Phase 3
Phase 4
Clinical Trials (1)
NCT00648674A Post-Marketing Clinical Study of Apligraf for Venous Leg Ulcers
Phase 4
Phase 4
Clinical Trials (1)
NCT01619670A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa
Phase 4
Apligraf
Venous Ulcer
Phase 4
Clinical Trials (1)
NCT01327937A Post Marketing Study of Apligraf in Non-healing Wounds of Subjects With Venous Leg Ulcers
Phase 4
Phase 4
Clinical Trials (1)
NCT02011724A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®
Phase 4

Open Jobs (4)

Production Associate Dermagraft

Smithfield, Rhode Island, United States
Production
2w ago
$24/hr

Program Manager, Regulatory Affairs

85 Dan Road, Canton, Massachusetts, 02021, United States
Regulatory Affairs
2w ago
$119K - $140K/yr

IT Support SpecialistII

Canton, Massachusetts, 02021, United States
Information Technology
2w ago
$27 - $28/hr

QC Analyst I/II -Microbiology

Unknown
Unknown
2w ago
Interview Prep Quick Facts
Founded: 2023
Portfolio: 37 clinical trials
SEC Filings: 2 available
Open Roles: 4 active jobs

Financials (FY2025)

Revenue
$433M4%
R&D Spend
$44M(10%)12%
Net Income
$5M
Cash
$136M
Source: SEC 10-K Filing